The Latest Cardiac and Vascular News
— Using optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI), physicians were able to select the right size stents and place them with greater precision — Imaging techniques such as OCT have been shown to improve outcomes during stenting procedures¹, but remain underutilized in global clinical settings due to lack […]
– New data reinforce Abbott’s leadership in minimally invasive treatment options for mitral and tricuspid repair and replacement therapies – Eleven late-breaking presentations at the PCR e-Course showcase impact of Abbott’s innovative structural heart portfolio on patient outcomes and quality of life in real-world and clinical settings ABBOTT PARK, Ill., June […]
– First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent – Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19) ABBOTT PARK, Ill., April 16, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2020. First-quarter worldwide sales of $7.7 billion increased 2.5 percent on […]
– CE Mark for TriClip represents an important treatment option for people with severe tricuspid regurgitation, a difficult-to-manage heart condition – New system offers a proven safe and effective minimally invasive non-surgical solution – The TriClip System leverages Abbott’s proven clip-based technology used in its MitraClip™ transcatheter mitral valve therapy […]
– New FlexNav™ delivery system improves control and delivery of the Portico™ TAVI valve even in complex clinical cases – The minimally invasive Portico procedure allows doctors to treat severe aortic valve stenosis without invasive surgery – Approval of the new delivery system follows first implants of the company’s next-generation […]
– New Gallant™ high voltage devices offer patients and their doctors a smartphone app and Bluetooth connectivity designed to help doctors tailor therapy to a patient’s unique clinical needs – Gallant ICD and CRT-D devices feature a more comfortable design, preferred by patients without compromising on battery longevity or high-voltage […]
ABBOTT PARK, Ill., Feb. 4, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the company has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its in-development Fully Implantable Left Ventricular Assist System (FILVAS). The FDA launched the Breakthrough Devices Program in 2018 to help expedite the development and review […]
– The CATALYST trial will examine Abbott’s Amplatzer™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation ABBOTT PARK, Ill., Feb. 3, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration […]
– First-of-its-kind technology addresses critical need to eliminate mitral regurgitation when surgery or mitral repair is not an option – Tendyne valve provides relief from heart failure symptoms and quality-of-life improvement in high-surgical-risk patients – Together with MitraClip™, Tendyne expands Abbott’s market-leading portfolio of innovative minimally invasive mitral valve solutions […]
– Fourth-quarter sales growth of 7.1 percent; organic sales growth of 8.5 percent – Fourth-quarter GAAP EPS growth from continuing operations of 59.5 percent and adjusted EPS growth from continuing operations of 17.3 percent – Several businesses achieved double-digit sales growth – Forecast reflects continued top-tier sales and earnings growth […]
